Bennicas & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $5.72M | Sell |
35,383
-925
| -3% | -$142K | 3.31% | 5 |
|
|
2022
Q3 | $4.87M | Sell |
36,308
-400
| -1% | -$57.4K | 3.11% | 5 |
|
|
2022
Q2 | $5.62M | Sell |
36,708
-75
| -0.2% | -$11.5K | 3.28% | 4 |
|
|
2022
Q1 | $5.96M | Sell |
36,783
-4,150
| -10% | -$603K | 2.99% | 4 |
|
|
2021
Q4 | $5.54M | Sell |
40,933
-175
| -0.4% | -$20.7K | 2.88% | 4 |
|
|
2021
Q3 | $4.43M | Sell |
41,108
-300
| -0.7% | -$34.3K | 2.49% | 5 |
|
|
2021
Q2 | $4.66M | Hold |
41,408
| – | – | 2.57% | 5 |
|
|
2021
Q1 | $4.48M | Sell |
41,408
-2,300
| -5% | -$246K | 2.57% | 5 |
|
|
2020
Q4 | $4.68M | Sell |
43,708
-350
| -0.8% | -$33.6K | 2.73% | 5 |
|
|
2020
Q3 | $3.86M | Sell |
44,058
-217
| -0.5% | -$20.4K | 2.4% | 8 |
|
|
2020
Q2 | $4.35M | Sell |
44,275
-350
| -0.8% | -$30.8K | 3.26% | 5 |
|
|
2020
Q1 | $3.4M | Sell |
44,625
-3,825
| -8% | -$326K | 3% | 6 |
|
|
2019
Q4 | $4.29M | Sell |
48,450
-6,200
| -11% | -$515K | 3.1% | 4 |
|
|
2019
Q3 | $4.14M | Buy |
54,650
+39,917
| +271% | +$2.74M | 3.21% | 4 |
|
|
2019
Q2 | $1.07M | Sell |
14,733
-210
| -1% | -$16.5K | 0.89% | 43 |
|
|
2019
Q1 | $1.2M | Sell |
14,943
-100
| -0.7% | -$8.18K | 1.06% | 37 |
|
|
2018
Q4 | $1.39M | Sell |
15,043
-100
| -0.7% | -$8.79K | 1.28% | 27 |
|
|
2018
Q3 | $1.43M | Hold |
15,143
| – | – | 1.24% | 27 |
|
|
2018
Q2 | $1.4M | Sell |
15,143
-50
| -0.3% | -$4.88K | 1.25% | 30 |
|
|
2018
Q1 | $1.44M | Sell |
15,193
-1,050
| -6% | -$115K | 1.28% | 27 |
|
|
2017
Q4 | $1.57M | Sell |
16,243
-1,400
| -8% | -$132K | 1.37% | 24 |
|
|
2017
Q3 | $1.57M | Sell |
17,643
-400
| -2% | -$30.4K | 1.33% | 25 |
|
|
2017
Q2 | $1.31M | Sell |
18,043
-67
| -0.4% | -$4.5K | 1.17% | 35 |
|
|
2017
Q1 | $1.18M | Sell |
18,110
-800
| -4% | -$50.3K | 1.05% | 38 |
|
|
2016
Q4 | $1.18M | Hold |
18,910
| – | – | 1.07% | 36 |
|
|
2016
Q3 | $1.19M | Sell |
18,910
-200
| -1% | -$12.9K | 1.09% | 35 |
|
|
2016
Q2 | $1.18M | Sell |
19,110
-600
| -3% | -$36.6K | 1.06% | 36 |
|
|
2016
Q1 | $1.13M | Sell |
19,710
-1,000
| -5% | -$55.7K | 1.07% | 32 |
|
|
2015
Q4 | $1.23M | Sell |
20,710
-20,000
| -49% | -$1.15M | 1.19% | 27 |
|
|
2015
Q3 | $2.21M | Sell |
40,710
-1,050
| -3% | -$68.3K | 2.06% | 11 |
|
|
2015
Q2 | $2.81M | Buy |
41,760
+9,950
| +31% | +$650K | 2.3% | 9 |
|
|
2015
Q1 | $1.86M | Sell |
31,810
-2,500
| -7% | -$151K | 1.56% | 19 |
|
|
2014
Q4 | $2.25M | Sell |
34,310
-1,000
| -3% | -$63K | 1.79% | 15 |
|
|
2014
Q3 | $2.04M | Sell |
35,310
-2,100
| -6% | -$117K | 1.68% | 16 |
|
|
2014
Q2 | $2.11M | Hold |
37,410
| – | – | 1.65% | 17 |
|
|
2014
Q1 | $1.92M | Sell |
37,410
-500
| -1% | -$25.3K | 1.54% | 21 |
|
|
2013
Q4 | $2M | Sell |
37,910
-3,200
| -8% | -$157K | 1.53% | 21 |
|
|
2013
Q3 | $1.84M | Sell |
41,110
-1,380
| -3% | -$61.2K | 1.33% | 35 |
|
|
2013
Q2 | $1.76M | Buy |
+42,490
| New | +$1.86M | 1.21% | 35 |
|
Other funds holding ABBV
AWA
Bennicas & Associates's ABBV Position: Q4 2022 in Review
Bennicas & Associates reduced its AbbVie (ABBV) stake by 2.5% in Q4 2022, selling an estimated $142K and leaving 35,383 shares worth $5.72M. The position accounts for 3.31% of the portfolio, ranked #5.
Bennicas & Associates first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $5.96M in Q1 2022. 3,167 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.
- Bennicas & Associates held 35,383 shares of AbbVie worth $5.72M as of Q4 2022.
- Bennicas & Associates sold 925 AbbVie shares in Q4 2022, an estimated $142K.
- AbbVie made up 3.31% of Bennicas & Associates's portfolio in Q4 2022, its #5 holding.
- Bennicas & Associates first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
- Bennicas & Associates's AbbVie position peaked at $5.96M in Q1 2022.
- 3,167 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.
Based on Bennicas & Associates's 13F filing for Q4 2022, filed 12 Jan 2023.